| Literature DB >> 32448264 |
Jinzhun Wu1,2, Dandan Ge1,3,4, Taoling Zhong5, Zuojia Chen6, Ying Zhou5, Lingyun Hou5, Xiaoliang Lin1,3,4, Jiaxu Hong7,8,9, Kuai Liu5, Hui Qi10, Chaoying Wang10, Yulin Zhou2, Cheng Li11, Chuan Wu6, Shuiping Wu12, Zuguo Liu11, Qiyuan Li13,14.
Abstract
BACKGROUND: Particulate Matter (PM) is known to cause inflammatory responses in human. Although prior studies verified the immunogenicity of PM in cell lines and animal models, the effectors of PM exposure in the respiratory system and the regulators of the immunogenicity of PM is not fully elucidated.Entities:
Keywords: Allergic respiratory disease; Gene expression profiling; Imbalanced T-cell differentiation; Particulate matters; Transcription factor
Mesh:
Substances:
Year: 2020 PMID: 32448264 PMCID: PMC7245756 DOI: 10.1186/s12931-020-01368-2
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Fig. 1Peripheral blood mononuclear cell (PBMC) expression profiling in a healthy population reveals co-expressed gene modules in association with PM exposure. a, enrollment of healthy subjects from three cities in north China, Beijing, Taiyuan and Shijiazhuang; b, Three-week average exposure level (μg/m3) of PM2.5 (left) and PM10 (right) of each enrolled subject from the three cities; c, PBMC gene expression profile generated from the enrolled subjects; d, 18 co-expressed gene modules retrieved from the PBMC gene expression profiles with correlation coefficients to the exposure levels of five major pollutants shown heat colors and e, integrating DNA motif, transcription factor activity and KEGG pathway to infer transcription factors underlying the co-expressed gene modules (* P < 0.05, ** P < 0.01, *** P < 0.001)
Summary of the subjects enrolled in the PBMC expression profiling study
| City | Gender | Age (year) | |||
|---|---|---|---|---|---|
| Female | Male | Median | Min | Max | |
| BeiJing | 15 (62.50%) | 9 (37.50%) | 29.5 | 23 | 48 |
| TaiYuan | 42 (80.77%) | 10 (19.23%) | 32 | 19 | 82 |
| ShiJiaZhuang | 35 (36.84%) | 60 (63.16%) | 43 | 21 | 80 |
Transcription factors (TF) underlying the co-expressed gene modules correlated with PM exposure (“cyan”, “brown”, “blue” and “turquoise”). TFs of which the binding motifs are significantly overrepresented in the co-expressed gene modules (FDR < 0.1); or the target genes are overrepresented in the eigen genes of each module (q-value < 0.05) are listed along with the KEGG pathways enriched (FDR < 0.05) in each module
| Co-expressed Modules | Binding motifs enriched in upregulated genes | Transcription factor activities | KEGG Pathway enrichment |
|---|---|---|---|
| Nrf2(bZIP); NFkB-p65(RHD); n-Myc (bHLH); PIF4(bHLH); RAR:RXR (NR); IRF (bZIP,IRF)/Th17-BatF | NFKB1, RELA, JUN, NFIC, CEBPB, REL, CEBPD, SP1, CTNNB1, CDX1, STAT1, DLX1, STAT6, RELB, STAT3, DLX2, CEBPG, BCL6, PDX1, TFAP2A, STAT2, GATA4, JUNB, GATA1, JUND, CREB1, YY1, FOS, LEF1 | Viral protein interaction with cytokine and cytokine receptor; IL-17 signaling pathway; Chemokine signaling pathway; Cytokine-cytokine receptor interaction; Salmonella infection; Rheumatoid arthritis; TNF signaling pathway; Fluid shear stress and atherosclerosis; Tuberculosis; NF-kappa B signaling pathway; AGE-RAGE signaling pathway in diabetic complications | |
| HOXA2(Homeobox); Hoxb4(Homeobox); STAT4(Stat);Pax7(Paired,Homeobox); E2A(bHLH); Stat3(Stat); STAT6(Stat) | MYC, SP1, TP53, STAT1, CEBPA, STAT3, HOXD3 | PD-L1 expression and PD-1 checkpoint pathway in cancer | |
| FOXP1(Forkhead); Fli1(ETS); GABPA (ETS); GATA3(Zf);RUNX-AML (Runt); E2A(bHLH); ox2(HMG); ETS1(ETS); Eomes(T-box) | MYC, TFAP2A, SP1, ETS1, SPI1, GLI2, USF1, SP2, RELA, SP3, ELK1, POU2F2, REL, STAT3, POU1F1, ETV4, RELB, FOXO3, NFKB1, USF2, RUNX1, FOXO1, E2F1, CTNNB1, MYB, E2F6, MYBL2, RARA, GLI1, PPARD, JUN, RARG, PAX6, NFYA, TP53 | Viral protein interaction with cytokine and cytokine receptor; ErbB signaling pathway; Epithelial cell signaling in Helicobacter pylori infection | |
| Fli1(ETS), ETS1(ETS); ELF1(ETS); Etv2(ETS); EABPA (ETS); Ets1-distal (ETS); RUNX (ETS,Runt) | CREB1, RBPJ, SP1, MYC, ATF1, CREBBP, SPI1, NFKB1, RELA, SREBF2, SREBF1, TP53, ETV4, E2F1, EGR1, FOXO1, NOTCH1, TFAP2A, YY1, BRCA1, BCL3, ETS1, TCF7L2, USF2, ATF6, JUN, STAT3, ESR1, CREM, PPARA, SMAD1, E2F6, FOXO3, PPARG, WT1, NFATC2, FLI1, RFX1, EGR4, OLIG1, FOXP1, CEBPB, PPARD, CTNNB1, ELK1, STAT5B, IRF9, STAT5A, ATF2, NFYA, GLI2, AR, USF1, STAT1, RELB, ID1, MYBL1, POU2F2, SMAD3, SMAD2, E2F4, ERG, FOXH1, CEBPA, REL, NFIC, ARNT, FEV, POU1F1, SP3, HOXA5, CEBPE, RARB, FOXO4, MYB, NFIA, NFATC1, SOX10, RARA, NR2F2, MITF, GABPA, HBP1, RARG, STAT2, SMAD4, HIF1A, NR1H2, NR1H3, TCF7, RUNX2, ATF4, NFE2L2, TBP, HNF4A, JUNB, NR2F1, CEBPD, GLI1, GATA1 | Lysine degradation; RNA degradation; N-Glycan biosynthesis; Ubiquitin mediated proteolysis; Valine, leucine and isoleucine degradation; Spliceosome; RNA transport; Hepatitis C; Propanoate metabolism; Cytosolic DNA-sensing pathway |
Fig. 2PM exposure alters T-cell polarization in vitro. a, flow cytometry analysis based on selected markers showing altered differentiation of Th1 (INFg, upper left), Th2 (IL4, IL13, lower left), Th17 (IL17, upper right) and Treg (FOXP3, lower right) in response to treatment with PM suspension (“PM”) as compared to control; b, the percentage of four T-cell subtypes with standard error are compared between PM-treated naïve T-cells and control; c, the expression levels of three predicted T-cell related transcription factors are compared between PM-treated naïve T-cells and control using qPCR (* P < 0.05, ** P < 0.01, *** P < 0.001)
Fig. 3Intranausal PM exposure causes inflammatory responses in mouse lung in vivo. a, the schematic view of the animal experiment, each group of six BALB/c mice were treated with PM suspension for 3 days before the lung tissue, BALF and serum were collected and analyzed; b, inflammatory alterations are observed in mouse lung following intranosal treatment of PM suspension; c, comparison of the pathological inflammation score in mouse lung tissue with and without PM treatment; d, Giemsa stain of cells in BALF from mice with and without PM treatment; E, the number of inflammation cells in BALF, include eosinophils, neutrophils, lymphocytes and macrophages. (* P < 0.05, ** P < 0.01, *** P < 0.001)
Fig. 4PM exposure alter T-cell polarization and cause Treg/Th17 imbalance in vivo. a, baseline-adjusted Th1, Th2, Th17 and Treg levels in mouse lung at 18 h, 24 h, 40 h and 72 h following PM treatment, respectively. Each treatment group contains six BALB/c mice; b, the Levels of each T-cell subtype are compared at each time point between PM-treated group and the control group; c, baseline-adjusted Th1/ Th2, Treg/Th17 ratios in mouse lung at 18 h, 24 h, 40 h and 72 h following PM treatment; d, the ratios of Th1/Th2, Treg/Th17 are compared between PM-treated group and the control group at each time point (* P < 0.05, ** P < 0.01, *** P < 0.001)
Fig. 5Predicted transcription factors of T-cell differentiation which are associated with PM exposure and the related cytokines change consistently in response to PM treatment in vivo. a, the expression levels of T-cell related transcription factors (Irf4, Batf4, Stat3) and IL-4 in mouse lung are measured using qPCR and compared between PM-treated group and the control group. Each treatment group contains six BALB/c mice; b, T-cell differentiation related cytokines in bronchoalveolar lavage fluid are measured using ELISA at 24 h following the treatment and compared between treatment group and control group (* P < 0.05, ** P < 0.01, *** P < 0.001)
Fig. 6The levels of phosphorylated Stat3 and Irf4 increases in mice lung tissues in response to PM exposure in vivo. Two groups of six BALB/c mice were treated with PM suspension for 3 days then after 24 h the lung tissue were collected for Western Blot assay. a, Western Blot showing the protein expression levels of phosphorylate-Stat3 (pStat3), un-phospho-Stat3 (Stat3), phosphorylate-Irf4 (pIrf4), un-phospho-Irf4 (Irf4) with beta-actin as control; b, the ratios of phosphorylate-Stat3 versus un-phospho-Stat3 and phosphorylate-Irf4 versus un-phospho-Irf4 increase significantly in response to PM treatment (* P < 0.05, ** P < 0.01, *** P < 0.001)